Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
A5397/HVTN 603 ID93 tuberculosis vaccine study
PACTR202605865966922Phase 2Not yet recruiting
- Sponsor
- National Institute of Allergy and Infectious Diseases
- Start
- Aug 2026
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Tuberculosis (TB) comparing ID93 + GLA-SE + standard tuberculosis treatment with Placebo injections + standard tuberculosis treatment (2 arms). Primary endpoints: Safety, Immunogenicity and 1 more. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
ID93GLA-SE adjuvant
03
Conditions
Tuberculosis (TB)
Beyond the preview
Go deeper on PACTR202605865966922.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202605865966922.